About Us
Powered by science. Fueled by collaboration.
Explore how our dedicated team pioneers viral-based gene therapy manufacturing technology to improve the lives of people with chronic health conditions.
Embracing Life. Delivering hope.
Welcome to FinVector, a leading cGMP manufacturer of viral-based products with a strong commitment to restoring hope, purpose and a true sense of belonging for those living with chronic health conditions.
Our state-of-the-art manufacturing facility is nestled in the thriving science and technology district of Savilahti, Kuopio, Finland, surrounded by stunning lakes and forests. This unique setting offers not only a dynamic work environment but also an exceptional quality of life.
FinVector has firmly established itself as a beacon of innovation in the cancer drug industry, gaining international recognition as a leader in Viral-Based Gene Therapy product manufacturing. Presently, FinVector produces a groundbreaking treatment for Non-Muscle Invasive Bladder Cancer, offering meaningful hope to countless patients worldwide.
Our work culture
Deliver for patients
Everything we do, we are driven by our commitment to improving the lives of people with chronic health conditions. We do this by excelling in the scientific manufacturing and delivery of viral-based gene therapy products with the highest standards of safety and efficacy.
Our mission is to deliver for patients.
Where science gives hope
- We innovate at the forefront of technology and scientific expertise
- We strive to be a global competence centre for viral-based gene therapy products
- We improve people’s quality of life and give them hope
- We are a people-first company
Putting people first
We firmly believe that the key to our success lies within our people and their unwavering dedication to their work and the well-being of others. We actively recruit talented individuals from across the globe, assembling a vibrant team of nearly 400 highly skilled professionals.
Our inclusive international community allows our employees to collaborate with other world-class experts who share a passion for improving health outcomes through cutting-edge science and manufacturing technology. We have thoughtfully cultivated a friendly, supportive, and well-structured environment that benefits the company’s mission and fosters both professional and personal growth for our employees.
FinVector is a dedicated partner in the fight against cancer. As an FDA-approved drug manufacturer, we work together with a meticulous attention to detail that ensures patient safety. We also possess a comprehensive understanding of and strict adherence to regulatory compliance, enabling us to fulfil our mission of delivering top-tier solutions and treatments to our partners.
Few of our employees could have imagined being part of an ambitious company that develops life-saving cancer therapies, especially here in this laid-back, nature-rich region of Finland. We are immensely proud to have them on board, and we invite you to join us in this vital fight.
Board of Directors
Giuseppe Carloni
Chairman of the board
Mr. Carloni served as the Managing Director of FinVector from July 2020 to December 2021 and as BLA Approval Director & QU Director until 15 October 2022. After the FDA inspection, he became a member of the board of FinVector and as of 1st of July 2023, Giuseppe was nominated as the Chairman of the board.
Bipin Dalmia
Board member
Mr. Dalmia is currently working as a Vice President, Strategy, Business Development and New Product Planning in Ferring USA. Bipin is responsible for all Ferring U.S. strategy, business development, and new product planning activities and is a key member of the Ferring Global Marketing and Business Development group.
Wolfram Carius
Board member
Mr. Carius is currently working as an Executive Vice President Cell and Gene Therapy in Bayer Pharmaceuticals. Wolfram has over 30 years of experience in Pharma and Biotech working in various countries such as Japan and the USA.
Jens Regelin
Board member
Mr. Regelin is currently working as a Senior Vice-President, Global Manufacturing Network at Ferring Pharmaceuticals.
Jean-Frédéric Paulsen
Board member
Mr. Paulsen is currently an Executive Chairman of the Ferring Group. Previously, Jean-Frédéric has been Chairman of Ferring Ventures SA and FinVector Oy during 2020-2023.
Site Leadership Team
Matthias Krieger
Managing Director
Carsten Hosbond
Manufacturing, Science and Technology (MSAT)
Mathieu Flechelle
Planning & Supply
Mikko Kämäräinen
Project Management Office
Taina van Eijsbergen
Quality Unit
Tiina Bies
People & Communication
Jouko Prami
Finance
Elisa Kajander
Manufacturing